PROTACs as a New Tactic to Treat Cancer
DOI:
https://doi.org/10.54097/k731dn36Keywords:
PROTAC, Cancer Therapy, Drug Resistance, Clinical Trials.Abstract
Cancer's high mortality, medication resistance, and recurrence rates make it a significant worldwide health concern. Despite improvements in immunotherapy and targeted therapy, its effectiveness is hampered by issues including acquired resistance. Among the innovative treatment approaches being investigated to address these issues, proteolysis-targeting chimeras (PROTACs) have shown promise. By selectively degrading target proteins, PROTACs provide a catalytic, long-lasting and low side effect mechanism of action in contrast to conventional small molecule inhibitors that impede protein function. In this review, the design, mechanisms, and uses of PROTACs in cancer treatment are examined. The development of PROTAC based cancer treatments is given a wider vision and additional alternatives thanks to this review, which also examines current issues like pharmacokinetics, cell membrane permeability, E3 ligase selection, and off-target effects et al. The information in this evaluation is intended to be used as a guide for future clinical translation and optimization of medications based on PROTACs.
Downloads
References
[1] Liao M, Qiang X, Sheng Z, Peng P. Mechanisms of drug resistance and coping strategies for small-molecule targeted anticancer drugs [J]. Progress in Pharmaceutical Sciences, 2023, 47 (9): 693–705.
[2] Zattoni, J., et al., A comprehensive primer and review of PROTACs and their in silico design. Comput Methods Programs Biomed, 2025. 264: p. 108687.
[3] Kim, H., J. Park, and J.M. Kim, Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway. Biomedicines, 2022. 10 (9).
[4] Ren, X., et al., PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy. Front Immunol, 2024. 15: p. 1392546.
[5] Wurz, R.P., et al., Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation. Nat Commun, 2023. 14 (1): p. 4177.
[6] Ocana, A. and A. Pandiella, Proteolysis targeting chimeras (PROTACs) in cancer therapy. J Exp Clin Cancer Res, 2020. 39 (1): p. 189.
[7] Danishuddin, et al., Revolutionizing Drug Targeting Strategies: Integrating Artificial Intelligence and Structure-Based Methods in PROTAC Development. Pharmaceuticals (Basel), 2023. 16 (12).
[8] Sobierajski, T., et al., The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation. Drug Discov Today, 2024. 29 (7): p. 104032.
[9] Cecchini, C., S. Tardy, and L. Scapozza, Linkers as Game-changers in PROTAC Technology: Emphasizing General Trends in PROTAC Pharmacokinetics for their Rational Design. Chimia (Aarau), 2022. 76 (4): p. 341-345.
[10] Lee, J., et al., Discovery of E3 Ligase Ligands for Target Protein Degradation. Molecules, 2022. 27 (19).
[11] Luo, X., et al., Profiling of diverse tumor types establishes the broad utility of VHL-based ProTaCs and triages candidate ubiquitin ligases. iScience, 2022. 25 (3): p. 103985.
[12] Grothusen, G.P., et al., DCAF15 control of cohesin dynamics sustain acute myeloid leukemia. Nat Commun, 2024. 15 (1): p. 5604.
[13] Dong, Y., et al., Characteristic roadmap of linker governs the rational design of PROTACs. Acta Pharm Sin B, 2024. 14 (10): p. 4266-4295.
[14] Poongavanam, V., et al., Linker-Dependent Folding Rationalizes PROTAC Cell Permeability. J Med Chem, 2022. 65 (19): p. 13029-13040.
[15] Khan, S., et al., PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer. Cells, 2024. 13 (6).
[16] Wang, Y., et al., In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC). Bioorg Chem, 2021. 111: p. 104833.
[17] Shi, Y.Y., et al., Stapled peptide PROTAC induced significantly greater anti-PD-L1 effects than inhibitor in human cervical cancer cells. Front Immunol, 2023. 14: p. 1193222.
[18] Su, W., et al., Targeted Degradation of PD-L1 and Activation of the STING Pathway by Carbon-Dot-Based PROTACs for Cancer Immunotherapy. Angew Chem Int Ed Engl, 2023. 62 (11): p. e202218128.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
